论文部分内容阅读
目的 观察卡维地洛对扩张型心肌病 (DCM)心力衰竭 (CHF)的临床疗效。方法 6 0例DCM并心力衰竭患者在利尿剂、洋地黄、ACEI及硝酸盐制剂治疗的基础上 ,随机分为卡维地洛治疗组及常规治疗组 (每组 30例 )。治疗前及 4月启用超声心动图测左室缩短分数 (FS) ,射血分数 (EF)、左室舒张末内径 (LVDD)、室间隔厚度 (IVS)和左室后壁厚度 (LVPW)。结果 治疗 4月后 ,两组心功能明显改善。卡维地洛组LVDD[6 1.5± 6 .6与 6 7.3± 6 .2 ,P <0 .0 5 ]、EF[4 8± 9.7与 4 0 .3± 6 .2 ,P <0 .0 5 ]、D/T[4 .1± 0 .7与 4 .6± 0 .5 ,P <0 .0 5 ]显著改善。结论 卡维地洛能显著改善DCM心力衰竭心功能及心肌重构
Objective To observe the clinical effect of carvedilol on dilated cardiomyopathy (DCM) with heart failure (CHF). Methods Sixty DCM patients with heart failure were randomly divided into carvedilol treatment group and conventional treatment group (30 cases in each group) on the basis of diuretic, digitalis, ACEI and nitrate preparations. Echocardiography was used to measure left ventricular ejection fraction (FS), ejection fraction (EF), left ventricular end diastolic diameter (LVDD), interventricular septum thickness (IVS) and left ventricular posterior wall thickness (LVPW) before and 4 months after treatment. Results After 4 months of treatment, heart function of both groups was significantly improved. LVDD in carvedilol group [6 1.5 ± 6.6 vs 6 7.3 ± 6.2, P <0.05], EF [48 ± 9.7 vs 40.3 ± 6.2, P <0.0 5], D / T [4 .1 ± 0 .7 and 4 .6 ± 0 .5, P <0. 05] significantly improved. Conclusion Carvedilol can significantly improve cardiac function and myocardial remodeling in DCM patients